How big is CervoMed, Inc.?

As of Jun 18, CervoMed, Inc. has a market capitalization of 61.44 million, with net sales of 9.31 million and a net profit of -18.67 million over the latest four quarters. The company reported shareholder's funds of 39.20 million and total assets of 43.46 million as of Dec 24.

Market Cap: As of Jun 18, CervoMed, Inc. has a market capitalization of 61.44 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, CervoMed, Inc. reported net sales of 9.31 million and a net profit of -18.67 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 39.20 million and total assets of 43.46 million.

What does CervoMed, Inc. do?

CervoMed, Inc. is a clinical-stage biotechnology company focused on developing cancer treatments that improve radiation and chemotherapy effectiveness by targeting tumor oxygen deprivation. It has a market cap of $61.44 million, with recent net sales of $2 million and a net loss of $5 million.

Overview: <BR>CervoMed, Inc. is a clinical-stage biotechnology company focused on developing treatments for cancer, specifically targeting tumor oxygen deprivation to enhance the effectiveness of radiation therapy and chemotherapy. The company operates in the Miscellaneous industry and falls within the micro-cap market bracket.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 61.44 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.02 <BR>Return on Equity: -53.91% <BR>Price to Book: 1.77<BR><BR>Contact Details: <BR>Address: 2020 Avon Ct Ste 4, CHARLOTTESVILLE VA : 22902-8734 <BR>Tel: 1 434 2200718 <BR>Fax: 1 434 2200722 <BR>Website: https://diffusionpharma.com/

Should I buy, sell or hold CervoMed, Inc.?

Is CervoMed, Inc. overvalued or undervalued?

As of May 10, 2023, CervoMed, Inc. is rated as "risky" and overvalued, with a Price to Book Value of 1.91, an EV to EBIT of -1.48, a ROE of -53.91%, and a 1-year stock return of -67.27%, significantly underperforming its peers and the S&P 500.

As of 10 May 2023, CervoMed, Inc. has moved from a valuation grade of "does not qualify" to "risky." The company is currently considered overvalued. Key ratios reveal a Price to Book Value of 1.91, an EV to EBIT of -1.48, and a ROE of -53.91%, indicating significant financial distress. <BR><BR>In comparison to peers, CervoMed's P/E ratio stands at -3.29, while Candel Therapeutics, Inc. has a P/E of -7.36 and Gaia, Inc. has a P/E of -21.71. These ratios highlight that CervoMed is not only underperforming relative to its peers but also facing severe challenges in generating positive earnings. The company's recent stock performance has significantly lagged behind the S&P 500, with a 1-year return of -67.27% compared to the index's 10.26%.

Is CervoMed, Inc. technically bullish or bearish?

As of July 21, 2025, CervoMed, Inc. shows a mildly bullish trend supported by positive MACD and daily moving averages, despite mixed signals from Bollinger Bands and Dow Theory, while significantly outperforming the S&P 500 year-to-date but underperforming in longer-term periods.

As of 21 July 2025, the technical trend for CervoMed, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. However, the Bollinger Bands are bearish on both weekly and monthly time frames, suggesting potential volatility. The daily moving averages are mildly bullish, supporting the overall positive stance. Dow Theory shows a mildly bearish weekly outlook but a mildly bullish monthly perspective, adding mixed signals. The KST is bullish weekly but bearish monthly, and the OBV is mildly bearish across both time frames.<BR><BR>In terms of returns, CervoMed has significantly outperformed the S&P 500 year-to-date with a return of 246.15% compared to the S&P 500's 12.22%, but it has underperformed over the longer term, particularly in the 1-year, 3-year, and 5-year periods. Overall, the current technical stance is mildly bullish, driven primarily by the MACD and daily moving averages, despite some bearish indicators present.